Vera Therapeutics

Patients

Patients are the reason for our existence. We strive to change the standard of care for patients with immunologic diseases.

IgAN

Up to 50% of IgAN patients progress to end-stage renal disease within 20 years from initial diagnosis, requiring dialysis or kidney transplant, which causes considerable impact on patients’ lives. Here are the stories of three courageous individuals with IgAN.
“The doctors told my parents and me that there was no cure, no proven treatment and that this disease would likely lead to kidney failure. I felt completely overwhelmed and also confused.”
“Living with IgA Nephropathy is a game-changer, and it will impact everything from what you eat to how you feel mentally every day. We need to move the needle to find a cure and a treatment for this disease.”
“When I was diagnosed, I was terrified. I was young so I did not really know what was going on, besides the fact that I am sick, and I am not going to get better. All I really remember is being scared and seeing my parents so scared and hurting.”
We are pleased to be partnering with:

Clinical Trials

The Phase 2b ORIGIN Study

The Phase 2b ORIGIN clinical trial is a dose-ranging study evaluating the safety and efficacy of atacicept in patients with IgA nephropathy (IgAN) who continue to have persistent proteinuria and remain at high risk of disease progression. Find out more here.

The Phase 2b ORIGIN study is a clinical trial to validate atacicept’s efficacy and safety in IgAN. Find out more here.

Clinicaltrials.gov is a regulatory public registry of clinical trials. To learn more about Vera or other clinical trials, their designs, purpose, eligibility criteria, and study locations, you can search at Clinicaltrials.gov.

Advocacy Resources

A patient-centric non-profit organization focused on finding a cure for IgA nephropathy through funding research, using patient advocacy to empower patients, and building a network of support.

BK Virus

Reactivation of BK Virus (BKV) can have serious consequences for immunocompromised patients, including kidney transplant and hematopoietic stem cell transplant (HSCT) recipients.

Clinical Trials

We are currently conducting a Ph2 study to evaluate efficacy and safety of MAU868 in the treatment of BK viremia in kidney transplant recipients. Find out more here.

Top